MARKET

QURE

QURE

Uniqure
NASDAQ

Real-time Quotes | Nasdaq Last Sale

29.83
+1.60
+5.65%
Opening 15:38 07/28 EDT
OPEN
28.30
PREV CLOSE
28.23
HIGH
29.93
LOW
28.30
VOLUME
367.79K
TURNOVER
--
52 WEEK HIGH
52.19
52 WEEK LOW
25.80
MARKET CAP
1.37B
P/E (TTM)
-9.6290
1D
5D
1M
3M
1Y
5Y
--Chardan Adjusts Price Target on uniQure to $95 From $100 on Q2 Earnings Results, Maintains Buy Rating
MT Newswires · 1d ago
--Credit Suisse Raises uniQure's PT to $81 from $78, Notes Pipeline Catalysts in H2, Keeps Outperform Rating
MT Newswires · 1d ago
UniQure (QURE) Q2 Earnings and Revenues Top Estimates
Zacks.com · 2d ago
BRIEF-Uniqure NV Q2 Revenue $463.9 Million
reuters.com · 2d ago
uniQure EPS beats by $6.91, beats on revenue
uniQure (QURE): Q2 GAAP EPS of $8.51 beats by $6.91.Revenue of $463.9M (+30023.4% Y/Y) beats by $320.92M.As of June 30, 2021, the Company’s cash position was $677.3M. The Company expects
Seekingalpha · 2d ago
uniQure Q2 EPS $8.51 Up From $(0.96) YoY
uniQure (NASDAQ:QURE) reported quarterly earnings of $8.51 per share. This is a 986.46 percent increase over losses of $(0.96) per share from the same period last year.
Benzinga · 2d ago
uniQure Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress
~ Expanded gene therapy pipeline with four new research programs and announced acquisition
GlobeNewswire · 2d ago
uniQure Q2 Net Earnings Turn Positive, Revenue Rises
MT Newswires · 2d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of QURE. Analyze the recent business situations of Uniqure through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 18 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average QURE stock price target is 67.09 with a high estimate of 95.00 and a low estimate of 40.00.
EPS
Institutional Holdings
Institutions: 258
Institutional Holdings: 41.59M
% Owned: 90.57%
Shares Outstanding: 45.92M
TypeInstitutionsShares
Increased
69
5.63M
New
19
694.77K
Decreased
40
2.04M
Sold Out
34
3.12M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.75%
Pharmaceuticals & Medical Research
+2.13%
Key Executives
Chief Executive Officer/Executive Director
Matthew Kapusta
Chief Financial Officer/General Manager
Christian Klemt
Corporate Executive
Ricardo Dolmetsch
Chief Operating Officer
Pierre Caloz
Executive Vice President
Alexander Kuta
Non-Executive Director
Robert Gut
Non-Executive Independent Director
Madhavan Balachandran
Non-Executive Independent Director
Jack Kaye
Non-Executive Independent Director
David Meek
Non-Executive Independent Director
Leonard Post
Non-Executive Independent Director
Paula Soteropoulos
Non-Executive Independent Director
Jeremy Springhorn
No Data
About QURE
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.

Webull offers kinds of Uniqure NV stock information, including NASDAQ:QURE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, QURE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading QURE stock methods without spending real money on the virtual paper trading platform.